This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Références
Omura GA, Brady MF, Homesley HD et al. (1991) Long term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 9: 1138–50
Van Der Burg MEL, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy ont the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–34
Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11: 166–72
Mc Guire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cacner. N Engl J Med 334: 1–6
Spano JP, Lucchi E, Sezeur A et al. (1998) Les tumeurs épithéliales malignes de l’ovaire (stade avancé). Bull cancer, suppl FMC 2: 5–23
Curé H (2004) Dose intensity in the treatment of advanced epithelial ovarian cancer: in Gynecologic cancer: Controversies in management. Gerhenson DM et al. Elsevier 479–89
Skipper HE (1990) Dose intensity versus total dose of chemotherapy: an experimental basis. In: Importance Advance in Oncology. De Vita VT, Hellman S, Rosenberg SA (Ed.). J.B. Lippin-cott 43–64
Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedule. Cancer Treat Rep 61: 1307–17
Goldie JH, Goldman AJ, Gudauskas GA (1982) Rationale for the use of alternating crossresistant chemotherapy. Cancer Treat Rep 66: 439–49
Rubin SC (1993) Second laparotomy in ovarian cancer. Cancer of the ovary. Markmann M., Hoskins WJ (Eds.). Raven Press Ltd, New-York
Levin L, Hryniuk WM (1987) Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756–67
Jodrell DI, Egorin MJ, Canetta RM et al. (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520–8
Ben-David Y, Rosen B, Franssen E et al. (1995) Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 59: 93–101
Kaye SB, Paul J, Cassidy J et al. (1996) Mature results of randomized trial of two doses of cisplatine for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 14(7): 2113–9
Ngan HY, Choo YC, Cheung M et al. (1989) A randomized study of high-dose versus lowdose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 35: 221–7
Murphy D, Crowther D, Renninson J et al. (1993) A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 4: 377–83
Bella M, Cocconi G, Lottici R et al. (1994) Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 5(suppl 8): 2
McGuire WP, Hoskins WJ, Brady MF et al. (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589–99
Rothenberg ML, Ozols RF, Glatstein E et al. (1992) Dose-intensive induction therapy with cyclophosphamide, cisplatin and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol 10: 727–34
Grem J, O’Dwyer P, Elson P et al. (1991) Cisplatin, carbo-platin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: en Eastern Cooperative Oncology Group pilot study. J Clin Oncol 9: 1793–800
Piccart MJ, Nogaret JM, Marcelis L et al. (1990) Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. J Natl Cancer Inst 82: 703–7
Fanning J, Hilgers RD (1993) High dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer. Gynecol Oncol 51: 182–6
Joly F, Heron JF, Kerbrat P et al. (2000) High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French comprehensive cancer centers (FNCLCC). Gynecol Oncol 78(3 Pt 1): 361–8
Thigpen T (1995) High-dose chemotherapy with autologous bone marrow support in ovarian carcinoma: the bottom line, more or less (Editorial). Gynecol Oncol 57:275–7
Cain JM, Ellis GK, Collins C et al. (1990) Bone marrow involvment in epithelial ovarian cancer by immunocytotechnical assessment. Gynecol Oncol 38: 442–5
Ron AA, Miller GW, Moss TJ et al. (1995) Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Bone Marrow Transplant 15: 929–33
Dal Cortivo L, Cottu PH, Lotz JP et al. (2001) Residual tumor cell contamination in peripheral blood stem cells collections of 117 breast cancer patients evaluated by immunocytochemical technique. J Hematother Stem Cell Res 10(6): 855–62
Pujade-Lauraine E, Cure H, Battista C et al. (2001) High dose chemotherapy in ovarian cancer Int J Gynecol Cancer 11 (Suppl 1): 64–7
Curé H, Extra JM, Viens P et al. (2000) High-dose chemotherapy as consolidation therapy for patients with platinum-sensitive advanced epithelial ovarian cancer. Bone Marrow Transplantation 26(1): S27–S29
M. Legros†, J. Dauplat, J. Fleury et al. (1997) J Clin Oncol 15: 1302–8
Extra JM, Curé H, Viens P et al. (1993) High dose chemotherapy with autologous bone marrow transplantation in ovarian adeno-carcinoma. Bull Cancer 80: 156–62
Curé H, Battista C, Guastalla JP et al. (2001) Phase III randomized trial of high-dose (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 20, abstract 815
Curé H, Battista C, Guastalla JP et al. (2004) Phase III randomized trial of high-dose (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 23, abstract 5006
Ledermann J, Herd R, Maraninchi D et al. (2001) High dose chemotherapy for ovarian carcinoma: long-term results from the solid tumour registry of the European Group for blood and Marrow Transplantation (EBMT). Annals of Oncology 12: 693–9
Shpall EJ, Cagnoni PJ, Bearman SI et al. (1995) High dose chemotherapy with autologous hematopoietic cell support (AHCS) for the treatment of epithelial ovarian cancer. 31st Annual Meeting of the American Society of Clinical Oncology, Los Angeles, Ca (USA), May 20-23 (Educational Book) pp. 360–4
Stiff P, Bayer R, Camarda M (1995) A phase II trial of high-dose mitoxantrone, carboplatine and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 57: 278–85
Stiff P, Bayer R, Kerger C et al. (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 4: 1309–17
Shinozuka T, Miyamoto T, Muramatsu T et al. (1999) High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients. Cancer 85(7): 1555–64
Curé H, D’Incan C, Bignon YJ et al. (1997) Immunothéapie du cancer de l’ovaire, passé, présent, futur. Références en gynécologie obstétrique 5(2): 161–8
Pujade-Lauraine E, Guastalla JP, Colombo N et al. (1996) Intraperiotoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 14: 343–50
Faradji A, Bohbot A, Frost H et al. (1991) Phase I of liposomal MTP-PE activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 9: 1251–60
Rights and permissions
Copyright information
© 2006 Springer-Verlag France
About this chapter
Cite this chapter
Curé, H., Bay, JO., Choufi, B., Chollet, P. (2006). Intensification de la chimiothérapie en consolidation. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_24
Download citation
DOI: https://doi.org/10.1007/2-287-30921-7_24
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-25168-9
Online ISBN: 978-2-287-30921-2